News | September 24, 2025
Alkem launches pertuzumab biosimilar ‘Pertuza’ for treatment of HER2-positive breast cancer
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Importantly, the combination of giredestrant and everolimus was well tolerated
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Subscribe To Our Newsletter & Stay Updated
